Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics to Participate in Upcoming Investor Conferences
04:00pm, Monday, 06'th Mar 2023
SOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere
Cytokinetics, Incorporated (CYTK) Q4 2022 Earnings Call Transcript
07:05pm, Wednesday, 01'st Mar 2023
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice President, Corporate Communications & Investor Relat
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
06:48pm, Wednesday, 01'st Mar 2023
Cytokinetics (CYTK) delivered earnings and revenue surprises of -18.85% and 73.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics will seek international approval for drug following FDA rejection, says CEO Robert Blum
03:10pm, Wednesday, 01'st Mar 2023
Cytokinetics President and CEO Robert Blum joins 'Power Lunch' to discuss the FDA's rejection of the company's heart failure drug, how FDA approval increases shareholder value and future treatment pla
Is a Surprise Coming for Cytokinetics (CYTK) This Earnings Season?
09:48am, Tuesday, 28'th Feb 2023
Cytokinetics (CYTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates
09:02am, Thursday, 23'rd Feb 2023
We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.
Cytokinetics to Announce Fourth Quarter Results on March 1, 2023
04:00pm, Wednesday, 15'th Feb 2023
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 1, 2023 at 4:00
Where To Now With Cytokinetics After The Omecamtiv Outcome?
04:41am, Friday, 06'th Jan 2023
The FDA's language in its recent briefing document for Cytokinetics' omecamtiv mercabil is a key factor to scrutinize. The FDA panel voted in a majority that the benefits may not outweigh the risks fo
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug
10:09am, Wednesday, 14'th Dec 2022
A "bruising" FDA meeting for Cytokinetics was actually a blessing in disguise, an analyst said Wednesday as CYTK stock surged. The post Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For I
Cytokinetics, Incorporated (CYTK) Q3 2022 Earnings Call Transcript
06:55am, Sunday, 06'th Nov 2022
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Diane Weiser - Senior Vice President, Corporate Communications & Investor Re
Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates
06:51pm, Thursday, 03'rd Nov 2022
Cytokinetics (CYTK) delivered earnings and revenue surprises of -7.56% and 11.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics: 2 Catalysts For Heart Failure Drug Make This Worth A Look
05:11am, Tuesday, 25'th Oct 2022
The FDA Advisory panel is expected to review Cytokinetics' omecamtiv mecarbil for the treatment of patients with heart failure on December 13, 2022. The FDA PDUFA date of omecamtiv mecarbil for the tr
Cytokinetics to Announce Third Quarter Results on November 3, 2022
04:00pm, Thursday, 20'th Oct 2022
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2022 at 4:0
Is Cytokinetics (CYTK) Outperforming Other Medical Stocks This Year?
11:17am, Friday, 14'th Oct 2022
Here is how Cytokinetics (CYTK) and Humana (HUM) have performed compared to their sector so far this year.
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv
01:32pm, Tuesday, 11'th Oct 2022
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
